List of Excipients in Branded Drug ADOXA

« Back to Dashboard

Generic Drugs Containing ADOXA

Company	Ingredient	NDC	Excipient
PharmaDerm a division of Fougera Pharmaceuticals Inc	doxycycline	10337-815	CELLULOSE, MICROCRYSTALLINE
PharmaDerm a division of Fougera Pharmaceuticals Inc	doxycycline	10337-815	FD&C RED NO. 40
PharmaDerm a division of Fougera Pharmaceuticals Inc	doxycycline	10337-815	FD&C YELLOW NO. 6

What are the Most Frequently-Used Excipients in ADOXA?

# Of NDCs	Excipient
1	CELLULOSE, MICROCRYSTALLINE
1	FD&C RED NO. 40
1	FD&C YELLOW NO. 6

ADOXA Excipient Strategy and Commercial Opportunities for Doxycycline Hyclate

Last updated: October 13, 2026

Adoxa is a legacy oral doxycycline product based on doxycycline hyclate. Its active-ingredient and basic salt patents are expired, leaving commercial differentiation to formulation performance, tolerability, lifecycle management, manufacturing efficiency, and regulatory execution. The strongest opportunities are low-dose, modified-release, taste-masked, and gastroprotective doxycycline products rather than a direct conventional-tablet copy.

What drug is ADOXA and what dosage forms does it use?

Adoxa is associated with doxycycline hyclate, a tetracycline-class antibacterial administered orally for susceptible bacterial infections and certain inflammatory dermatologic conditions. Historical Adoxa labeling covered tablet strengths including 50 mg, 75 mg, and 100 mg doxycycline equivalent products, depending on the marketed presentation and labeling version. The product was supplied as an immediate-release oral solid dosage form. [1]

Doxycycline has broad clinical use in:

• Acne and rosacea
• Chlamydial infections
• Respiratory infections
• Tick-borne diseases
• Malaria prophylaxis
• Periodontal infections
• Certain inflammatory skin disorders

The molecule is commercially attractive because it has high prescription volume across primary care, dermatology, infectious disease, and public-health channels. The direct generic market is competitive, but differentiated dosage forms can support higher pricing and lower substitution risk.

What is the active pharmaceutical ingredient?

The active pharmaceutical ingredient is doxycycline, generally supplied as doxycycline hyclate or doxycycline monohydrate.

Doxycycline hyclate is a hygroscopic salt. Its formulation profile creates several excipient requirements:

• Moisture control
• Protection from light and humidity
• Compatibility with acidic and alkaline excipients
• Control of dissolution across gastric conditions
• Reduction of esophageal retention risk
• Acceptable tablet size at low and high strengths
• Protection against degradation and discoloration

Doxycycline is also associated with gastrointestinal irritation and esophageal injury when taken with insufficient water or immediately before lying down. That clinical issue creates a direct formulation opportunity.

What patents protect Adoxa and doxycycline products?

The core doxycycline composition-of-matter patent estate is expired. Adoxa does not present the same patent barrier associated with a newer branded small molecule. Commercial risk therefore turns on formulation patents, process patents, regulatory exclusivity, trademarks, and manufacturing know-how.

What is the Orange Book status of Adoxa?

Adoxa is a legacy doxycycline product listed in FDA product databases under the doxycycline hyclate category. Conventional doxycycline hyclate tablets are generally exposed to abbreviated new drug application competition, and no meaningful unexpired core patent protection should be assumed for the conventional immediate-release product. [1, 2]

The relevant Orange Book questions are:

Issue	Commercial assessment
Active-ingredient patent	Expired
Conventional tablet protection	Weak or absent
Paragraph IV exposure	Relevant only where an unexpired listed patent exists
Pediatric exclusivity	Not a durable current barrier for legacy Adoxa
Orphan exclusivity	Not applicable to the conventional product
New formulation opportunity	Potentially protectable
Trademark protection	Separate from drug patent protection
Manufacturing know-how	Potentially valuable but difficult to enforce against independent production

The Orange Book must be reviewed by product-specific NDA and strength because listings can change over time. A conventional generic applicant would normally rely on an ANDA with a Paragraph III or Paragraph IV certification depending on the patent record. [2, 3]

When does Adoxa lose exclusivity?

Adoxa’s meaningful exclusivity loss occurred with the expiration of the underlying doxycycline patent estate and the expansion of generic doxycycline supply. The product should be analyzed as a mature generic market rather than as a protected branded asset.

The practical exclusivity timeline is:

Period	Market position
Original launch period	Branded doxycycline product with conventional oral-solid positioning
Patent-expiry period	Generic entry became available
Post-expiry period	Price competition and manufacturer substitution increased
Current lifecycle phase	Value depends on formulation differentiation, supply reliability, and channel strategy

A new product using the same active ingredient can create a separate exclusivity timeline if it has a novel dosage form, approved indication, pediatric indication, or other qualifying regulatory feature. The relevant protection would attach to the new product, not revive exclusivity for conventional Adoxa tablets.

How should excipients be selected for an Adoxa-like product?

The excipient strategy should match the target product: conventional generic, improved immediate-release tablet, delayed-release capsule, or differentiated dermatology product.

Immediate-release doxycycline hyclate tablets

A conventional tablet can use a standard platform based on:

• Microcrystalline cellulose as a diluent and compression aid
• Crospovidone or croscarmellose sodium as a disintegrant
• Povidone as a binder where needed
• Colloidal silicon dioxide as a glidant
• Magnesium stearate as a lubricant
• Film-coating polymers for handling, appearance, and light protection

The formulation should minimize excipient-driven changes in doxycycline dissolution. Excessive alkalinity, high moisture exposure, and unsuitable reducing or oxidizing components can increase stability risk.

An immediate-release product has the lowest development cost and the shortest regulatory path if it is pharmaceutically equivalent to the reference product. It also has the lowest pricing power.

Moisture-protective film coating

A protective film coat can provide commercial value without substantially changing the product’s release profile. Suitable coating functions include:

• Moisture barrier protection
• Light protection
• Improved swallowability
• Reduced tablet dusting
• Product identification
• Better stability in high-humidity markets

Hypromellose-based coatings are common for oral solid dosage forms. Polyvinyl alcohol systems can provide stronger film performance. Titanium dioxide or approved colorants can support opacity and identification, subject to current regulatory requirements and market-specific restrictions.

The commercial opportunity is strongest where the product has a documented stability advantage, longer in-use shelf life, or better packaging efficiency. A coating alone is unlikely to create a strong patent position unless the composition, process, or performance is distinctive.

Delayed-release or enteric-coated doxycycline

A delayed-release design can separate doxycycline release from the upper gastrointestinal tract. The goal is to reduce local irritation and improve patient handling while maintaining adequate exposure.

Potential excipient systems include:

• Methacrylic acid copolymers
• Cellulose acetate phthalate
• Hypromellose phthalate
• Plasticizers such as triethyl citrate
• Subcoats that protect the drug from the enteric polymer
• Anti-tacking agents such as talc or colloidal silica

The formulation must control:

• Acid resistance
• Release at intestinal pH
• Dose dumping
• Food effects
• Storage stability
• Particle-size distribution
• Capsule or tablet fill uniformity

A delayed-release product has greater patent potential than a standard tablet because the release profile, coating architecture, and dosing regimen can support composition and method-of-use claims. The market already includes modified-release doxycycline products, so freedom-to-operate analysis is essential before development.

Low-dose doxycycline for inflammatory conditions

Low-dose doxycycline products can target anti-inflammatory treatment rather than antimicrobial therapy. A sub-antimicrobial dose may reduce selection pressure while maintaining efficacy in conditions such as acne or rosacea, depending on the approved indication and clinical evidence.

The excipient design should support:

• Small, easy-to-swallow units
• Accurate low-dose content uniformity
• Minimal dissolution variability
• Reduced gastric irritation
• Stable performance across fed and fasted conditions

Low-dose products can support premium pricing if they obtain a distinct indication or demonstrate clinically meaningful tolerability. Patent claims may focus on dose, dosing interval, formulation, and treatment method.

What formulation patents could protect a new doxycycline product?

The strongest formulation patent categories are:

Patent category	Potential claim focus
Modified release	Enteric coating, delayed release, pulsatile release
Taste masking	Ion exchange, polymer coating, multiparticulate systems
Gastroprotection	Reduced esophageal exposure or lower gastric irritation
Stability	Moisture-controlled composition or degradation suppression
Multiparticulates	Pellets, beads, granules, or minitablets
Pediatric delivery	Suspensions, dispersible tablets, flavored granules
Low dose	Sub-antimicrobial dosing and inflammatory indications
Combination product	Doxycycline with another active ingredient
Manufacturing	Controlled granulation, coating, drying, or crystallization

Patent strength depends on claim breadth, prior art, reproducibility, and the ability to detect infringement. A narrow formulation patent covering a particular polymer ratio may be enforceable but commercially weak if competitors can design around it.

A stronger estate would combine:

1. Composition claims covering the excipient architecture.
2. Process claims covering manufacture.
3. Method claims covering the clinical use.
4. Specifications supporting multiple strengths and dosage forms.
5. Continuation applications preserving claim flexibility.

Which commercial opportunities are available for Adoxa-derived products?

1. Generic immediate-release tablets

This is the lowest-risk opportunity. It requires established bioequivalence, reliable API supply, and competitive cost of goods. Margins are generally compressed because doxycycline has many generic suppliers.

The best commercial position comes from:

• Reliable supply
• Short backorder history
• Multiple strengths
• Competitive hospital contracts
• Private-label partnerships
• Efficient packaging and serialization

2. Gastrointestinal-tolerability product

A delayed-release or gastroprotective product can target patients who discontinue conventional doxycycline because of nausea, reflux, or esophageal discomfort. Clinical claims must remain within the approved label unless supported by new evidence and regulatory review.

This strategy has higher development cost but offers greater differentiation. It also faces existing competition from delayed-release doxycycline products.

3. Dermatology-focused low-dose product

A branded low-dose product can target dermatologists treating acne, rosacea, and inflammatory skin disorders. The commercial case depends on a distinct label, payer acceptance, and evidence that the product avoids unnecessary antimicrobial exposure.

Dermatology is attractive because prescribing is concentrated among specialists, treatment duration can be extended, and patient experience can support brand retention.

4. Pediatric liquid or dispersible formulation

Liquid doxycycline products can address swallowing limitations, pediatric dosing, and institutional use. Doxycycline’s historical concern regarding dental staining in young children has been narrowed by modern evidence and updated clinical guidance, but regulatory labeling remains critical. [4]

Excipient priorities include:

• Palatability
• Suspension uniformity
• Microbial control
• Sedimentation control
• Dose-measuring accuracy
• Reconstitution stability
• Low sugar or sugar-free options

A ready-to-use suspension has convenience advantages but higher stability and packaging requirements. A powder for reconstitution can improve shelf life but adds preparation steps.

5. Combination and adherence products

Combination products could pair doxycycline with an active targeting a related dermatologic or infectious indication. Such products face more complex clinical and regulatory requirements, but they may reduce pill burden and support differentiated intellectual property.

What manufacturing and IP barriers affect commercialization?

Doxycycline products have several technical barriers despite the absence of core-molecule exclusivity.

API and salt-form control

Doxycycline hyclate quality depends on:

• Assay
• Water content
• Residual solvents
• Related substances
• Particle-size distribution
• Solid-state properties
• Microbiological quality

Changes in API source can alter blend uniformity, dissolution, compaction, and stability. A supplier change may require additional comparability work.

Coating and drying controls

Modified-release products require consistent coating weight, polymer distribution, plasticizer level, and curing conditions. Small process changes can shift dissolution and create batch failures.

Analytical methods

Release testing should include:

• Assay and impurities
• Dissolution across multiple pH stages
• Water content
• Content uniformity
• Stability-indicating degradation methods
• Microbial limits for liquids
• Reconstitution performance where applicable

Geographic coverage

The commercial strategy should separate United States, European Union, and emerging-market requirements. FDA approval does not establish European or other national market authorization. Excipient acceptability, colorant restrictions, packaging rules, and bioequivalence standards vary by jurisdiction.

A global product should use excipients with broad regulatory acceptance and avoid formulation choices that require different compositions in major markets.

How strong is the patent estate for an Adoxa lifecycle product?

The patent strength of conventional Adoxa is low. The patent strength of a new doxycycline formulation can range from weak to moderate, depending on differentiation.

Product concept	Patent strength	Commercial attractiveness
Conventional immediate-release tablet	Low	Low to moderate
Moisture-protective tablet	Low to moderate	Moderate
Delayed-release capsule	Moderate	Moderate to high
Low-dose dermatology product	Moderate	High if clinically differentiated
Pediatric suspension	Moderate	Moderate
Taste-masked multiparticulate	Moderate to high	Moderate
Combination product	Moderate to high	Depends on indication
Novel delivery system	High potential	High development risk

A formulation patent should not be treated as strong solely because it covers a new excipient combination. The key questions are whether the formulation delivers a measurable clinical or pharmaceutical benefit, whether competitors can substitute another excipient, and whether infringement can be proven from public product information.

What litigation and Paragraph IV risks exist?

Conventional doxycycline products have a history of intense generic competition and pricing pressure. Any new formulation may face:

• Paragraph IV challenges against listed patents
• ANDA litigation over formulation claims
• Patent-term and regulatory-exclusivity disputes
• Trade-secret disputes involving manufacturing
• Antitrust scrutiny where supply or licensing arrangements restrict competition
• Patent challenges from established generic manufacturers

A Paragraph IV strategy is most relevant for a new branded formulation with Orange Book-listed patents. A conventional Adoxa-like tablet is more likely to face routine ANDA competition than high-value patent litigation.

Settlement agreements require review for entry dates, authorized-generic provisions, supply rights, and restrictions on formulation development. No commercial conclusion should rely on patent expiration alone if a settlement has created an earlier or conditional generic-entry date.

What licensing opportunities exist?

Potential licensing structures include:

• In-licensing a delayed-release doxycycline technology
• Out-licensing a low-dose dermatology formulation
• Contract manufacturing of coated multiparticulates
• Regional commercialization rights
• Authorized-generic supply agreements
• Co-development with a dermatology specialist
• API supply and dual-source manufacturing agreements

The highest-value asset is likely a formulation with clinical differentiation and a defensible regulatory package. A license covering only conventional doxycycline hyclate tablets is unlikely to command strong economics unless it includes a reliable supply advantage or an established distribution network.

Key Takeaways

• Adoxa is a legacy doxycycline hyclate oral product with no meaningful core-molecule exclusivity.
• Conventional immediate-release tablets are commercially exposed to generic competition.
• Excipient selection should prioritize moisture control, dissolution consistency, tolerability, and manufacturability.
• Delayed-release, low-dose dermatology, pediatric, and taste-masked products offer the clearest lifecycle opportunities.
• Formulation patents are more valuable when supported by clinical, dissolution, stability, or adherence advantages.
• Paragraph IV risk is material for new Orange Book-listed formulations but limited for conventional doxycycline tablets.
• Commercial success will depend more on product differentiation, supply reliability, and regulatory execution than on the legacy Adoxa brand.

FAQs

Is Adoxa still a patent-protected doxycycline product?

No. Adoxa is a legacy doxycycline product, and conventional doxycycline patent protection has expired. New protection would need to arise from a separately developed formulation, indication, dosage regimen, or manufacturing process.

Can a new doxycycline tablet use the same excipients as Adoxa?

It can use similar excipients if the formulation meets applicable quality, bioequivalence, stability, and regulatory requirements. The exact historical Adoxa composition should not be assumed to be necessary or optimal for a new product.

Is doxycycline hyclate or doxycycline monohydrate better for lifecycle management?

Neither is universally superior. Doxycycline hyclate may support established immediate-release products, while doxycycline monohydrate can be attractive where tolerability, solid-state behavior, or formulation performance supports differentiation.

What doxycycline formulation has the strongest commercial opportunity?

A differentiated delayed-release or low-dose dermatology product generally offers greater commercial potential than another conventional immediate-release tablet, provided it has a distinct label and defensible patent claims.

Can excipients alone create new doxycycline exclusivity?

Excipients can support patentable formulation claims, but the formulation must be novel, non-obvious, adequately described, and commercially meaningful. Routine substitution of one standard excipient for another is unlikely to provide durable exclusivity.

References

1. U.S. Food and Drug Administration. (n.d.). Adoxa: Doxycycline hyclate prescribing information. Drugs@FDA.
2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. Orange Book.
3. U.S. Food and Drug Administration. (2024). Abbreviated new drug application submissions and Paragraph IV certifications.
4. American Academy of Pediatrics. (2018). Red Book: 2018-2021 report of the Committee on Infectious Diseases. American Academy of Pediatrics.